Amylin Pharma (AMLN) Posts Wider than Expected Q2 Loss; Revs Beat
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharma (NASDAQ: AMLN) reported Q2 loss of ($0.21), $0.03 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $158.07 million versus the consensus estimate of $157.72 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- P&G lifts annual profit forecast on strong US consumer demand, easing costs
- American Express (AXP) Tops Q1 EPS by 38c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
